Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB3008 in advanced solid tumors
NCT06143007Phase 1Active, not recruiting
- Sponsor
- BroadenBio Co., Ltd.
- Start
- Oct 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BB3008 in solid tumor (advanced stage), sponsored by BroadenBio Co., Ltd. Primary endpoints: Dose Limiting Toxicities at 21 days and Adverse Events and Serious Adverse Events at 12 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
BB3008
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06143007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143007.